AstraZeneca: Amgen leaves AstraZeneca alone with brodalumab

NEUTRAL, Fair Value 4830p vs. 4860p (+8%)
News published on May Tuesday 26, 2015
Share on

Amgen has decided to terminate the agreement on brodalumab because suicidal ideation should negatively impact the label of the drug. AstraZeneca now has to decide what to do with it. We are cutting by half the PoS of brodalumab in our model to 30%, reducing the FV to 4,830p.


For more information, please contact marketing@bryangarnier.com 


The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities